About PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals is a publicly listed company based in Malvern (United States) founded in 2002. Novel drugs are developed for metabolic and cardiopulmonary disorders. PhaseBio Pharmaceuticals has raised $152.38 million across 11 funding rounds from investors including SVB, Astrazeneca and NIH. The company has 39 employees. Its chief executive, as recorded, is Jonathan Mow. Its focus areas include Life Sciences, Metabolic Diseases and Drugs. Its competitors include NGM Biopharmaceuticals, MannKind Corp and Rhythm Pharmaceuticals; 3 of its 3 listed competitors have raised funding.
Company details
PhaseBio Pharmaceuticals was founded in 2002 and is headquartered in Malvern, United States. Operations focus on the biotechnology sector, where novel therapeutics are developed to address metabolic and cardiopulmonary disorders. Elastin-like biopolymers are utilized in these developments to enhance drug half-life and bioavailability, while side effects and costs are minimized. The portfolio encompasses Bentracimab as an antiplatelet agent, Pemziviptadil for pulmonary arterial hypertension, and PB6440 for hypertension management.
- Headquarters Malvern, United States
- Employees 39
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website phasebio.com
- Social LinkedIn X
- Annual Revenue$10.83 M (USD)3285as on Dec 31, 2021
- Total Equity Funding$152.38M (USD)
in 11 rounds
- Latest Funding Round$34M (USD), Series D
Sep 2018
- InvestorsSVB
& 13 more
- Employee Count39
Funding Insights of PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals has successfully raised a total of $152.38M across 11 strategic funding rounds. The most recent funding activity was a Series D round of $34 million completed in September 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $152.38M
- Total Rounds 11
- Last Round Series D — $34M
- First Round $458,144
(Sep 2006)
- Investors Count 14
Latest 10 of 11 funding rounds of PhaseBio Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2018 | $34M | Series D | – | Rock Springs Capital, Mountain Group Partners | |
| Feb 2018 | $2.8M | Grant | – | – | |
| Feb 2018 | $2.77M | Grant | – | – | |
| Nov 2017 | $7.5M | Debt – Conventional | – | – | |
| Nov 2017 | $8.1M | Series C | – | – | |
| Jan 2017 | $14.7M | Series C | – | – | |
| Mar 2015 | $40M | Series C | – | Astrazeneca | |
| Jun 2012 | $48.52M | Series B | – | New Enterprise Associates, Astellas Venture Management | |
| Nov 2009 | $999,999 | Debt – Conventional | – | – | – |
| Oct 2007 | $6.6M | Series B | – | Johnson & Johnson Innovation, Fletcher Spaght |
14 investors in total: 14 institutional.
Investors in PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include SVB, Astrazeneca and NIH.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Venture capital firm backed by Johnson & Johnson | jnjinnovation.com/jjdc | Cambridge, United States | ||
Tech & Life Sciences focused VC firm investing in early stage companies in the US & Europe | hatterasvp.com | Durham, United States | ||
Syno Capital is focused on healthcare investment and innovation. | 2015 | synocapital.com | New York, United States | |
| astellasventure.com | ||||
Early-stage and late-stage biotech and finance companies are funded. | rockspringscapital.com | Baltimore, United States | ||
Venture capital is directed toward life sciences and technology sectors. | mtngp.com | Nashville, United States | ||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Banking services are provided to innovative companies, investors, and individuals. | 1983 | svb.com | Santa Clara, United States |
Investor details for PhaseBio Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of PhaseBio Pharmaceuticals
17 people are tracked at PhaseBio Pharmaceuticals (2 in leadership, 12 in board & advisors, 3 in team); the tracked headcount is 39.
| Name | Role | Group |
|---|---|---|
Jonathan Mow | CEO | Leadership |
John Lee | Chief Medical Officer | Leadership |
Pradeep P.A. Mammen | Advisor | Board & advisors |
Ashutosh Chilkoti | Advisor | Board & advisors |
Jeffrey I. Weitz | Advisor | Board & advisors |
Cam Patterson | Advisor | Board & advisors |
Raymond L. Benza | Advisor | Board & advisors |
Robert Hamlin | Advisor | Board & advisors |
R. James White | Advisor | Board & advisors |
Deepak L. Bhatt | Advisor | Board & advisors |
Edmund Harrigan | Director | Board & advisors |
Clay Thorp | Chairman | Board & advisors |
Richard Van Den Broek | Director | Board & advisors |
Nancy Hutson | Director | Board & advisors |
Kris Hanson | SVP & General Counsel | Team |
Susan Arnold | SVP, Technical Operations | Team |
Gina Wildman | Senior Accountant | Team |
Complete people profiles for PhaseBio Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of PhaseBio Pharmaceuticals
4 dated milestones of PhaseBio Pharmaceuticals across 16 years, from founding to its latest funding, stage changes and deals.
- Founded PhaseBio Pharmaceuticals is founded.
- Funding First funding round of $458K.
- Funding Latest funding round, Series D, of $34.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include NGM Biopharmaceuticals, MannKind Corp and Rhythm Pharmaceuticals.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ngmbio.com | 2007 | San Francisco, United States | $358.87M | 225 | Biologics are developed for cardio-metabolic and liver diseases. | |
| mannkindcorp.com | 1991 | Los Angeles, United States | $50M | 322 | Developer of small-molecule drugs | |
| rhythmtx.com | 2010 | Boston, United States | $84M | 115 | Developer of peptide therapeutics for the treatment of rare genetic deficiencies |
Detailed competitors of PhaseBio Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of PhaseBio Pharmaceuticals
The website of PhaseBio Pharmaceuticals (phasebio.com) receives about 2.2K visits a month and ranks #11,529,454 among all websites worldwide, #8,129 in Biotechnology and Pharmaceuticals.
- Monthly visits2.2K
▲ 97.5% vs previous month
- Global rank#11,529,454
among all websites
- Category rank#8,129
Health · Biotechnology and Pharmaceuticals
- Bounce rate35%
- Pages per visit2.4
- Average visit1 min 11 sec
- DevicesDesktop 33% · Mobile 67%
Websites whose visitors overlap most with PhaseBio Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| clinipace.com | 100% | View details | |||
| santhera.com | 92% | 12.6K | #3,177,070 | View details | |
| madrigalpharma.com | 91% | 54.4K | #889,142 | View details | |
| aqxpharma.com | 91% | 3K | #6,768,702 | View details | |
| adamaspharma.com | 90% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 9 similar websites and full traffic analytics for PhaseBio Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 9 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Metabolic Diseases
3 companies that operate in the same segment as PhaseBio Pharmaceuticals (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Phasebio Pharmaceuticals
Complete news archive for PhaseBio Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals was founded in 2002 and raised its 1st funding round 4 years after it was founded.
PhaseBio Pharmaceuticals is headquartered in Malvern, United States. It is registered at Malvern, Pennsylvania, United States.
Jonathan Mow is the CEO of PhaseBio Pharmaceuticals, as recorded in our data.
PhaseBio Pharmaceuticals is a funded company, having raised a total of $152.38M across 11 funding rounds to date. The company's 1st funding round was a Series B of $6.6M, raised on Sep 2006.
PhaseBio Pharmaceuticals has 39 employees.
Annual revenue of PhaseBio Pharmaceuticals is $10.83M as on Dec 31, 2021.
PhaseBio Pharmaceuticals was founded in 2002 and is headquartered in Malvern, United States. Operations focus on the biotechnology sector, where novel therapeutics are developed to address metabolic and cardiopulmonary disorders. Elastin-like biopolymers are utilized in these developments to enhance drug half-life and bioavailability, while side effects and costs are minimized. The portfolio encompasses Bentracimab as an antiplatelet agent, Pemziviptadil for pulmonary arterial hypertension, and PB6440 for hypertension management.
PhaseBio Pharmaceuticals's top competitors include Rhythm Pharmaceuticals, MannKind Corp and NGM Biopharmaceuticals.
PhaseBio Pharmaceuticals has 14 investors. Key investors include SVB, Astrazeneca, NIH, HHS, and Fletcher Spaght.